Ian M. Evans
1 Midland Road
London, ENG, United Kingdom
London, ENG, United Kingdom
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 30 publications
Exosomal circFXR1 drives immune evasion and tumor progression through dual regulation of PD-L1 and mTOR signaling in gastric cancer.
Journal: Cancer letters
Published: April 07, 2026
Correction: PARP1 inhibitor combined with oxaliplatin efficiently suppresses oxaliplatin resistance in gastric cancer-derived organoids via homologous recombination and the base excision repair pathway.
Journal: Frontiers in cell and developmental biology
Published: July 24, 2025
SPP1 is required for maintaining mesenchymal cell fate in pancreatic cancer.
Journal: Nature
Published: November 25, 2024
Evaluating COVID-19 cases reported across prisons in England from 2020 to 2023: Is enhanced address matching a game-changer for surveillance?
Journal: Public health
Published: November 21, 2024
NBS1 lactylation is required for efficient DNA repair and chemotherapy resistance.
Journal: Nature
Published: April 18, 2023
Ductal Ngn3-expressing progenitors contribute to adult β cell neogenesis in the pancreas.
Journal: Cell stem cell
Published: April 07, 2023
Safer children, healthier lives: reducing the burden of serious accidents to children.
Journal: Paediatrics and child health
Published: June 09, 2022
USP7 controls NGN3 stability and pancreatic endocrine lineage development.
Journal: Nature communications
Published: May 25, 2022
Co-immunoprecipitation Assays.
Journal: Methods in molecular biology (Clifton, N.J.)
Published: April 22, 2022
Depot- and diabetes-specific differences in norepinephrine-mediated adipose tissue angiogenesis, vascular tone, collagen deposition and morphology in obesity.
Journal: Life sciences
Published: March 09, 2022
METTL3 promotes oxaliplatin resistance of gastric cancer CD133+ stem cells by promoting PARP1 mRNA stability.
Journal: Cellular and molecular life sciences : CMLS
Published: September 27, 2021
PARP1 Inhibitor Combined With Oxaliplatin Efficiently Suppresses Oxaliplatin Resistance in Gastric Cancer-Derived Organoids via Homologous Recombination and the Base Excision Repair Pathway.
Journal: Frontiers in cell and developmental biology
Published: June 02, 2021
Last Updated: 09/26/2026